Diagnostic Simplification
Cross-source consensus on Diagnostic Simplification from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Risks & contraindications
Comparisons
Highlighted claims
- Antibody tests indicate exposure to hepatitis C but do not confirm current infection. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
- Unavailable, costly, or centralised confirmatory RNA testing can cause delays and loss to follow-up after antibody screening. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
- Confirmatory RNA or core antigen tests require more infrastructure, skills, referral pathways, and costs than antibody testing. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
- Diagnostic affordability and accessibility are major barriers as treatment has become cheaper. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
- Point-of-care or near-point-of-care PCR systems can improve access but still require infrastructure, trained workers, and cartridges. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol